Latest investigations into retatruptide peptide highlight notable possibility for treating obesity and non-insulin dependent disease. The peptide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, looks to present improved body mass and glucose regulation compared existing therapies. Additional clinical trials are necessary